This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP
by Zacks Equity Research
Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.
Nevro's (NVRO) 10 kHz Therapy for Treatment of PDN Gets Coverage
by Zacks Equity Research
Nevro (NVRO) receives coverage for its high-frequency 10 kHz therapy for the treatment of PDN.
Nevro (NVRO) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Nevro (NVRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass
by Zacks Equity Research
Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -1.16% and 2.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nevro (NVRO) Up 8.6% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro (NVRO) Q2 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues rise on a year-over-year basis in Q2 despite pandemic-led business challenges.
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 12.68% and -2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
by Zacks Equity Research
Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.
Why Is Nevro (NVRO) Down 6.3% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investors' confidence is high in Nevro (NVRO) stock, courtesy of its solid prospects.
Nevro (NVRO) Stock Slips 2.9% Despite Narrower Loss in Q1
by Zacks Equity Research
Nevro's (NVRO) international revenues rise on a year-over-year basis in Q1.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 1.16% and 4.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nevro (NVRO) Down 16% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.
Nevro (NVRO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
by Zacks Equity Research
Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.
Why Is Nevro (NVRO) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.